drugset / Trial / NCT05571111
Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary purpose of this trial is to compare three different doses of FE 999302 with 250 µg OVITRELLE and 10,000 IU NOVAREL on oocyte maturity when administered as a single dose for final development of the oocytes in women undergoing controlled ovarian stimulation.
Timeline
- Start
- 2022-10-04
- Primary completion
- 2024-03-25
- Completion
- 2024-06-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FE 999302 | Protein / enzyme biologic | — | Subcutaneous |
| Comparator | Novarel | Unknown | 10000 iu | Subcutaneous |
| Comparator | Ovidrel | Protein / enzyme biologic | 250 ug | Subcutaneous |